- Home
- MHI vs STTK Comparison
MHI vs STTK Comparison
Compare MHI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHI
- STTK
- Stock Information
- Founded
- MHI 2003
- STTK 2016
- Country
- MHI United States
- STTK United States
- Employees
- MHI N/A
- STTK N/A
- Industry
- MHI Investment Managers
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MHI Finance
- STTK Health Care
- Exchange
- MHI Nasdaq
- STTK Nasdaq
- Market Cap
- MHI 208.1M
- STTK 37.6M
- IPO Year
- MHI N/A
- STTK 2020
- Fundamental
- Price
- MHI $9.19
- STTK $0.82
- Analyst Decision
- MHI
- STTK Hold
- Analyst Count
- MHI 0
- STTK 4
- Target Price
- MHI N/A
- STTK $3.00
- AVG Volume (30 Days)
- MHI 98.8K
- STTK 396.2K
- Earning Date
- MHI 01-01-0001
- STTK 07-31-2025
- Dividend Yield
- MHI 4.09%
- STTK N/A
- EPS Growth
- MHI N/A
- STTK N/A
- EPS
- MHI 0.04
- STTK N/A
- Revenue
- MHI N/A
- STTK $4,606,000.00
- Revenue This Year
- MHI N/A
- STTK N/A
- Revenue Next Year
- MHI N/A
- STTK N/A
- P/E Ratio
- MHI $219.25
- STTK N/A
- Revenue Growth
- MHI N/A
- STTK 69.65
- 52 Week Low
- MHI $6.93
- STTK $0.69
- 52 Week High
- MHI $9.05
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- MHI 54.94
- STTK 37.21
- Support Level
- MHI $9.08
- STTK $0.77
- Resistance Level
- MHI $9.19
- STTK $1.14
- Average True Range (ATR)
- MHI 0.05
- STTK 0.09
- MACD
- MHI 0.00
- STTK -0.03
- Stochastic Oscillator
- MHI 71.43
- STTK 9.88
About MHI Pioneer Municipal High Income Fund Inc.
Pioneer Municipal High Income Trust is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income exempt from regular federal income tax and capital appreciation. The trust invests in various sectors such as health, education, tobacco, facilities, transportation, utilities, airport, water, and other sectors.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.